Why the study?
Does adriamycin improve tumor response in a patient with metastatic squamous cell carcinoma of the prostate refractory to other treatments?
Does adriamycin improve tumor response in a patient with metastatic squamous cell carcinoma of the prostate refractory to other treatments?
Adriamycin may provide a durable response in patients with metastatic squamous cell carcinoma of the prostate refractory to standard therapies.
May support adriamycin in refractory prostatic squamous carcinoma; hypothesis-generating and should not change practice without further study.
A case is presented of a 67-year old man who experienced the sudden onset of prostatism and underwent a complete panendoscopy and transurethral resection of the prostate. Tissue from the right lateral lobe of the prostatic urethra revealed squamous cell carcinoma and a chest x-ray revealed bilateral pulmonary nodules. Tumor progression was observed. However, subsequent response to adriamycin has lasted more than 5 months after the carcinoma failed to respond to radiation, surgery or other chemotherapy.
No takes yet. Share an insight, caveat, or question.
Corder et al. (1976) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: